

## Appendix

### Claims as pending:

1. An anti-IFNAR2 monoclonal antibody which blocks the binding of a first type I interferon to IFNAR2 and does not block the binding of a second type I interferon to IFNAR2.
2. The antibody of claim 1, wherein the second type I interferon is IFN- $\beta$ .
3. The antibody of claim 2, wherein the first type I interferon is selected from the group consisting of IFN- $\alpha$ B, IFN- $\alpha$ G, IFN- $\alpha$ A, and IFN- $\alpha$ D.
4. The antibody of claim 3, wherein the antibody blocks the binding of IFN- $\alpha$ B, IFN- $\alpha$ G, IFN- $\alpha$ A, and IFN- $\alpha$ D to IFNAR2.
5. (Amended) An anti-IFNAR2 monoclonal antibody that competes for binding to IFNAR2 with an antibody selected from the group consisting of IF3 (ATCC HB 12426), 3B7 (ATCC HB 12427) and 1D3 (ATCC HB 12428).
6. An anti-IFNAR2 monoclonal antibody selected from the group consisting of: (1) an antibody that binds to one or more of amino acid positions 49, 51, 52 or 54 in situ in the extracellular domain of IFNAR2 (amino acid positions 1-216 of SEQ ID NO.26); (2) an antibody that binds to one or more of amino acid positions 68, 71 or 72 in situ in the extracellular domain of IFNAR2 (amino acid positions 1-216 of SEQ ID NO.26); (3) an antibody that binds to one or more of amino acid positions 133, 134, 135 or 139 in situ in the extracellular domain of IFNAR2 (amino acid positions 1-216 of SEQ ID NO.26); (4) an antibody that binds to one or more of amino acid positions 153, 154 or 156 in situ in the extracellular domain of IFNAR2 (amino acid positions 1-216 of SEQ ID NO.26); (5) an antibody that binds to one or more of amino acid positions 74, 77 or 78 in situ in the extracellular domain of IFNAR2 (amino acid positions 1-216 of SEQ ID NO.26); and (6) an antibody that binds to one or more of amino acid positions 105 or 109 in situ in the extracellular domain of IFNAR2 (amino acid positions 1-216 of SEQ ID NO.26).
9. The anti-IFNAR2 monoclonal antibody of claim 6 that (a) binds to one or more of amino acid positions 153, 154 or 156 in situ in the extracellular domain of IFNAR2 (amino acid positions 1-216 of SEQ ID NO.26); and (b) binds to one or more of amino acid positions 133, 134, 135 or 139 in situ in the extracellular domain of IFNAR2 (amino acid positions 1-216 of SEQ ID NO.26).

Serial No.: 09/166,298  
Filed: October 5, 1998

10. The anti-IFNAR2 monoclonal antibody of claim 9 that is 1D3.